Country Lead, Flow Neuroscience
Germany
+ Share options
Medically certified depression treatment at home
Job no longer available
Medically certified depression treatment at home
21-100 employees
Job no longer available
+ Share options
21-100 employees
Company mission
To revolutionise the treatment of mental illness, to enable everyone to live their best life.
Jump to section
Company mission
To revolutionise the treatment of mental illness, to enable everyone to live their best life.
Our take
Despite the prevalence of mental health conditions such as anxiety and depression, medicine has been relatively slow to respond with new treatment options. Particularly, at-home treatment has been limited to medication, or more recently virtual talk therapy. Flow Neuroscience has developed a wearable tDCS (transcranial Direct Current Stimulation) device for patients to use at home, with a complementary app to help manage the symptoms of major depressive disorder.
Flow's device delivers a gentle electrical current to the part of the brain that regulates mood, offering a non-drug alternative that patients can use outside of a clinical setting under remote supervision. The treatment has already been used by more than 55,000 people across Hong Kong, the UK, Switzerland and other parts of Europe. Clinical research has produced promising results, including studies showing that a significant proportion of patients experience symptom improvement within weeks of starting treatment.
In a major milestone for the company, the US Food and Drug Administration approved Flow's FL-100 headset to treat moderate to severe major depressive disorder in adults. This approval makes it the first at-home brain stimulation device cleared for depression treatment in the US. With this, the company plans to launch the device in the US later in 2026 as a prescription treatment, expanding its reach and bringing its technology to a much larger patient population.
Kirsty
Company Specialist at Welcome to the Jungle
Funding (last 2 of 3 rounds)
Aug 2021
$9.9m
SERIES A
Jul 2019
$1.6m
EARLY VC
Total funding: $12.5m
This company has top investors
Leadership
Daniel Månsson
(Co-Founder & Chief Science Officer)After co-founding Flow Neuroscience in 2015, Daniel served as the CEO until 2022. Previously, he was a Clinical Psychology at Sykehuset Østfold.
Erik M. Rehn
(Co-Founder & CTO)Erik is also the co-founder of Skry, where he currently serves as a Board Member. Previously, he co-founded Stockholm.AI where he served a the VP.
Erin Sivyer Lee
(CEO)Prior to joining Flow Neuroscience in 2022, Erin was the VP of Global Operations & USA Managing Director at Babylon and the Director of Community Operations Northern Europe and Middle East & Head of EMEA Innovation at Uber. She also spent 8 years at Google as an Analyst/Program Lead and in New Product Strategy & Operations.